MTIM
ESPR

Marathon Trading Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Marathon Trading Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31,070
Closed -$69K – 292
2024
Q2 		$69K Sell
31,070
-139,430
-82% -$328K 0.01% 234
2024
Q1 		$457K Buy
170,500
+149,500
+712% +$363K 0.03% 179
2023
Q4 		$62.8K Buy
+21,000
New +$27.2K ﹤0.01% 312

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marathon Trading Investment Management's ESPR Position: Q3 2024 in Review

Marathon Trading Investment Management sold out of Esperion Therapeutics (ESPR) in Q3 2024, closing a stake of 31,070 shares — an estimated $69K sold.

Marathon Trading Investment Management first reported a position in ESPR in Q4 2023 and held it in 3 quarters. The position peaked at $457K in Q1 2024. 183 funds tracked by Wall St. Rank hold ESPR as of Q3 2024.

  • Marathon Trading Investment Management reported no remaining Esperion Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 31,070 Esperion Therapeutics shares in Q3 2024, an estimated $69K.
  • Marathon Trading Investment Management first reported a position in Esperion Therapeutics in Q4 2023 and held it in 3 quarters.
  • Marathon Trading Investment Management's Esperion Therapeutics position peaked at $457K in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2024.

Based on Marathon Trading Investment Management's 13F filing for Q3 2024, filed 7 Nov 2024.